Clearmind Medicine 提交了 MDMA、伊博加因和氯胺酮与棕榈酰乙醇酰胺化合物的 PCT 专利申请。 Clearmind Medicine submits PCT patent applications for MDMA, Ibogaine, and Ketamine compounds with Palmitoylethanolamide.
Clearmind Medicine 是一家专注于致幻剂的生物技术公司，根据专利合作条约 (PCT)，针对 MDMA、伊博加因和氯胺酮化合物提交了三项新的国际专利申请。 Clearmind Medicine, a psychedelic-focused biotech firm, has submitted three new international patent applications under the Patent Cooperation Treaty (PCT) for MDMA, Ibogaine, and Ketamine compounds. 该专利申请涉及含有棕榈酰乙醇酰胺 (PEA) 的新型专有组合物，棕榈酰乙醇酰胺是 SciSparc 专有 CannAmide 中的一种活性成分。 The patent applications involve novel proprietary compositions with Palmitoylethanolamide (PEA), an active ingredient in SciSparc's proprietary CannAmide. 此次合作增强了 Clearmind 的知识产权保护，并扩大了其在迷幻领域的领导地位。 This collaboration enhances Clearmind's intellectual property protection and expands its leadership in the psychedelic space.